Datatrak grows revenues, op income & backlog in Q2

By Nick Taylor

- Last updated on GMT

Related tags: Datatrak, Income, Income statement

Datatrak has posted an operating profit, grown revenues and recorded the forth consecutive quarter-on-quarter increase in backlog in its latest results.

Revenue in the second quarter was $1.9m (€1.5m), a year-on-year increase of three per cent. However, this is still down on the performance in the second quarter of 2008, when Datatrak generated revenue of $2.2m.

Sales growth in the second quarter helped Datatrak record an operating profit of $27,290. In the corresponding period of 2009 Datatrak posted an operating loss of $36,181, primarily as a result of severance expenses.

Datatrak also continued to grow its backlog. As of June 30 backlog was $10.9m, up year-on-year by 27 per cent. However, this is again lower than historic levels, such as the $13.2m backlog Datatrak had on June 30 2008.

Despite this, Laurence Birch, chairman of the Datatrak board, was bullish about the company’s prospects. He said: “The word is getting out that Datatrak is back in the game, as evidenced by the significant increase in traffic through our booth at the recent DIA meeting​.”

At DIA Datatrak generated 500 qualified leads, said Birch, and it also exhibited at the 2010 ASCO annual meeting and presented at the 2010 OneMedForum as part of continued marketing efforts.

In the second quarter Datatrak expanded its strategic partnership in Japan with NTT Data. The revised partnership allows NTT to sell enterprise transfer services in Japan and has entered into its first agreement in this area, generating additional revenues for both partners.

Datatrak has also inked a deal with its first Portuguese client, Keypoint Scientific Consultancy, and been selected by Daiichi Sankyo for a cardiovascular trial in Europe. Daiichi will use Datatrak’s eClinical platform for the trial, which spans 80 sites and 1,200 patients.

Related topics: Clinical Development, Data management

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more